IgM antibody against thyroglobulin did not show any statistically significant difference at the baseline among those who developed hepatitis, compared with baseline samples from patients who did not experience irAEs (p=0.16, FC (fold change): -1.5, FDR: 0.39); and at the time of hepatitis when compared with controls (p=0.354, FC: 1.4, FDR: 0.99). This evidence concerns the gene CD40LG and hepatitis A virus infection.